Business Wire

Lenovo Commits to Net-Zero Emissions by 2050, Validated by Science Based Targets initiative

Share

Today, Lenovo (HKSE: 992) (ADR: LNVGY) announced its goal to reach net-zero greenhouse gas (GHG) emissions by 2050, validated and approved by the Science Based Targets initiative (SBTi), a partnership between the UN Global Compact, CDP and World Wide Fund for Nature – making it the first PC and smartphone maker and one of only 139 companies in the world with a net-zero target validated by SBTi.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005499/en/

By working with SBTi and aligning to their Net-Zero Standard (the world’s first), Lenovo is taking a scientific, collaborative and accountable approach to reducing emissions.

“As a global technology leader, Lenovo has been committed to reducing its emissions for more than a decade,” said Lenovo Chairman Yuanqing Yang. “In the fight against climate change, we believe collaboration and accountability are the two critical elements needed for collective success. We remain dedicated to following climate science, standardizing our measurements, and seeking ongoing validation for our targets and progress.”

Aligning goals to the SBTi helps hold companies accountable for their emissions reduction. Without aligning to SBTi, it is difficult to validate or know when a net-zero target is reached. This is because:

  1. Standardization: SBTi is the first body to standardize what net-zero means as it relates to the effort to limit global warming to 1.5 degrees Celsius.
  2. Adaptation: SBTi’s standard is dynamic and responsive to companies’ collective effort and the changing temperature of the planet.
  3. Accountability: While 2050 seems far away for many, many leaders making commitments today may not be in their positions in 27 years. Aligning goals to reduce climate change to an external body provides accountability and continuity.

“Climate science tells us that we need rapid and deep emissions cuts if we are to achieve global net-zero and prevent the most damaging effects of climate change,” said Luiz Amaral, Chief Executive Officer of the Science Based Targets initiative. “Lenovo’s net-zero targets match the urgency of the climate crisis and set a clear example that their peers must follow.”

Lenovo’s long-term 2050 goals coincide with its near-term, SBTi-validated 2030 emissions reduction goals, all of which are outlined below:

Overall Net-Zero Target

Lenovo commits to reach net-zero GHG emissions across the value chain by FY2049/2050.

Near-Term Targets

Lenovo commits to reduce absolute scope 1 and scope 2 GHG emissions 50% by FY2029/2030 from a FY2018/2019 base year. Lenovo also commits to reduce scope 3 GHG emissions from use of sold products 35% on average for comparable products within the same timeframe. Lenovo commits to reduce scope 3 GHG emissions from purchased goods and services 66.5% per million US$ gross profit within the same timeframe. Lenovo further commits to reduce scope 3 GHG emissions from upstream transportation and distribution 25% per tonne-km of transported product by within the same timeframe.

Long-Term Targets

Lenovo commits to reduce absolute scope 1, 2, and 3 GHG emissions by 90% by FY2049/50 from a FY2018/19 base year.

Lenovo is an early adopter of the science-based emissions reduction approach, after receiving approval for near-term 2030 emissions reduction goals in 2020 and helping to road test the first of its kind Net-Zero Standard.

“Success in achieving net-zero depends on a transparent, science-based and collaborative framework that will keep organizations accountable for the long run. SBTi has created that framework and will empower companies to expedite emissions reduction,” commented Carolina Milanesi, Founder of The Heart of Tech, an ESG-focused consultancy.

Primary strategies for reducing Lenovo’s emissions include reducing the environmental impact of its products, harnessing innovation to increase sustainability in its manufacturing, and decreasing emissions across its operations and value chain. These strategies have been outlined in the company’s Journey to Net-Zero video series, which demonstrates how Lenovo’s experts are changing business processes to meet net-zero targets.

Lenovo’s emissions measurements will contribute to a wider body of collaborative data to understand and limit climate change, in accordance with the Paris Agreement’s goal to limit warming to no more than 1.5 degrees Celsius above pre-industrial levels. More than 4,000 companies around the world are in the process of aligning their emissions reduction goals to SBTi’s science-based methodology and validation processes.

In addition to its work to reduce emissions, Lenovo has been recognized in Gartner’s Top 25 Global Supply Chain, Fortune’s World’s Most Admired Companies, and as a leader in Climate Change and Water Security by CDP. Read more about Lenovo’s efforts to create a smarter, more sustainable future for all in the company’s FY 2021-22 ESG Report.

For more information visit Lenovo StoryHub.

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 82,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into key growth areas including server, storage, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com,and read about the latest news via our StoryHub.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

sgill@lenovo.com
+44 (0)7917 437 532

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye